Aquestive Therapeutics, Inc. AQST Interest limitation imposed by the TCJA
Interest limitation imposed by the TCJA at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept aqst:TaxCutsAndJobsActOf2017DeferredTaxAssetsInterestLimitation.
The official record: Aquestive Therapeutics, Inc.’s 10-K, filed March 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s interest limitation imposed by the tcja.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s interest limitation imposed by the TCJA?
- Aquestive Therapeutics, Inc. (AQST) reported interest limitation imposed by the TCJA of $11.39M in Q4 2025.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s interest limitation imposed by the TCJA?
- Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s interest limitation imposed by the TCJA has grown at a 7.4% compound annual growth rate (CAGR), from $9.88M to $11.39M.
- What does interest limitation imposed by the TCJA mean?
- This represents deferred tax assets arising from limitations on the deductibility of interest expense under the Tax Cuts and Jobs Act. It reflects the future tax benefit available to the company when these disallowed interest expenses become deductible in future periods. Monitoring this helps investors understand the company's future tax shield potential and the impact of tax legislation on cash flow.